Immunosuppressive therapy for transplant-ineligible aplastic anemia patients

References

• Young NS, Calado RT, Scheinberg P. Current concepts on in the pathophysiology and treatment of aplastic anemia. Blood 2006;108:2509-19
   PubMed Web of Science ®Google Scholar
• Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol 2008;15:162-8
   PubMed Web of Science ®Google Scholar
• Maury S, Bacigalupo A, Anderlini P, et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica 2009;94:1312-15
   PubMed Web of Science ®Google Scholar
• Passweg JR, Socie G, Hinterberger W, et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood 1997;90:858-64
   PubMed Web of Science ®Google Scholar
• Viollier R, Socie G, Tichelli A, et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant 2008;41:45-50
   PubMedGoogle Scholar
• Passweg JR, Marsh JC. Aplastic anemia: first-line treatment by immunosuppression and sibling marrow transplantation. Hematology Am Soc Hematol Educ Program 2010;2010:36-42
   PubMedGoogle Scholar
• Valdez JM, Scheinberg P, Nunez O, et al. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis 2011;52:726-35
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Socie G, Schrezenmeier H, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica 2012;97:1142-8
   PubMed Web of Science ®Google Scholar
• Sakaguchi H, Nishio N, Hama A, et al. Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemia. Haematologica 2014;99:1312-16
   PubMedGoogle Scholar
• Li X, Shi J, Ge M, et al. Outcomes of optimized over standard protocol of rabbit antithymocyte globulin for severe aplastic anemia: a single-center experience. PLoS One 2013;8:e56648
   PubMed Web of Science ®Google Scholar
• Eapen M, Rademacher J, Antin JH, et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood 2011;118:2618-21
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007;110:1397-400
   PubMed Web of Science ®Google Scholar
• European Blood and Marrow Transplant Group, Severe Aplastic Anaemia Working Party. Rabbit ATG for aplastic anaemia treatment: a backward step? Lancet 2011;378:1831-3
   PubMedGoogle Scholar
• Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011;365:430-8
   PubMed Web of Science ®Google Scholar
• Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood 2012;119:5391-6
   PubMed Web of Science ®Google Scholar
• Young ME, Potter V, Kulasekararaj AG, et al. Haematopoietic stem cell transplantation for acquired aplastic anaemia. Curr Opin Hematol 2013;20:515-20
   PubMedGoogle Scholar
• Bacigalupo A, Marsh JC. Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18. 40 years without an HLA-identical sibling and failing immunosuppression. Bone Marrow Transplant 2013;48:198-200
   PubMedGoogle Scholar
• Bacigalupo A. Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation? Hematology Am Soc Hematol Educ Program 2012;2012:223-9
   PubMedGoogle Scholar
• Frickhofen N, Heimpel H, Kaltwasser JP, et al. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236-42
   PubMed Web of Science ®Google Scholar
• Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med 1991;324:1297-304
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Wu CO, Nunez O, et al. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol 2009;144:206-16
   PubMed Web of Science ®Google Scholar
• Rosenfeld S, Follmann D, Nunez O, et al. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003;289:1130-5
   PubMed Web of Science ®Google Scholar
• Rosenfeld SJ, Kimball J, Vining D, et al. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995;85:3058-65
   PubMed Web of Science ®Google Scholar
• Tichelli A, Schrezenmeier H, Socie G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 2011;117:4434-41
   PubMed Web of Science ®Google Scholar
• Teramura M, Kimura A, Iwase S, et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 2007;110:1756-61
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy–The European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000;37:69-80
   PubMed Web of Science ®Google Scholar
• Marsh JC, Socie G, Schrezenmeier H, et al. Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Lancet 1994;344:172-3
   PubMedGoogle Scholar
• Fuhrer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood 2005;106:2102-4
   PubMed Web of Science ®Google Scholar
• Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006;107:1308-14
   PubMed Web of Science ®Google Scholar
• Brummendorf TH, Maciejewski JP, Mak J, et al. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood 2001;97:895-900
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005;352:1413-24
   PubMed Web of Science ®Google Scholar
• Vulliamy T, Marrone A, Dokal I, et al. Association between aplastic anaemia and mutations in telomerase RNA. Lancet 2002;359:2168-70
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Cooper JN, Sloand EM, et al. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA 2010;304:1358-64
   PubMed Web of Science ®Google Scholar
• Saracco P, Quarello P, Iori AP, et al. Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol 2008;140:197-205
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Rios O, Scheinberg P, et al. Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia. Am J Hematol 2014;89:571-4
   PubMedGoogle Scholar
• Alsultan A, Goldenberg NA, Kaiser N, et al. Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children. Pediatr Blood Cancer 2009;52:626-30
   PubMedGoogle Scholar
• Macartney C, Freilich M, Odame I, et al. Complete response to tacrolimus in a child with severe aplastic anemia resistant to cyclosporin A. Pediatr Blood Cancer 2009;52:525-7
   PubMedGoogle Scholar
• Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000;95:1931-4
   PubMed Web of Science ®Google Scholar
• Gluckman E, Rokicka-Milewska R, Hann I, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol 2002;119:1075-82
   PubMed Web of Science ®Google Scholar
• Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000;96:2049-54
   PubMed Web of Science ®Google Scholar
• Gurion R, Gafter-Gvili A, Paul M, et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica 2009;94:712-19
   PubMed Web of Science ®Google Scholar
• Socie G, Mary JY, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007;109:2794-6
   PubMed Web of Science ®Google Scholar
• Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997;90:1009-13
   PubMed Web of Science ®Google Scholar
• Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol 2006;34:826-31
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Nunez O, Wu C, et al. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, cyclosporin and mycophenolate mofetil. Br J Haematol 2006;133:606-11
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Wu CO, Nunez O, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 2009;94:348-54
   PubMed Web of Science ®Google Scholar
• Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012;367:11-19
   PubMed Web of Science ®Google Scholar
• Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 2014;123:1818-25
   PubMed Web of Science ®Google Scholar
• de Laval B, Pawlikowska P, Petit-Cocault L, et al. Thrombopoietin-increased DNA-PK-dependent DNA repair limits hematopoietic stem and progenitor cell mutagenesis in response to DNA damage. Cell Stem Cell 2013;12:37-48
   PubMed Web of Science ®Google Scholar
• Laval B, Pawlikowska P, Barbieri D, et al. Thrombopoietin promotes NHEJ DNA repair in hematopoietic stem cells through specific activation of Erk and NF-kappaB pathways and their target, IEX-1. Blood 2014;123:509-19
   PubMedGoogle Scholar
• Ballmaier M, Germeshausen M, Schulze H, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001;97:139-46
   PubMed Web of Science ®Google Scholar
• Ballmaier M, Germeshausen M, Krukemeier S, et al. Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia. Ann N Y Acad Sci 2003;996:17-25
   PubMed Web of Science ®Google Scholar
• Qian H, Buza-Vidas N, Hyland CD, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell 2007;1:671-84
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Nunez O, Weinstein B, et al. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 2012;119:345-54
   PubMed Web of Science ®Google Scholar
• Kim H, Min YJ, Baek JH, et al. A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk Res 2009;33:222-31
   PubMed Web of Science ®Google Scholar
• Risitano AM, Selleri C, Serio B, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol 2010;148:791-6
   PubMed Web of Science ®Google Scholar
• Risitano AM, Schrezenmeier H. Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: campath (Alemtuzumab). Bone Marrow Transplant 2013;48:186-90
   PubMed Web of Science ®Google Scholar
• Gomez-Almaguer D, Jaime-Perez JC, Garza-Rodriguez V, et al. Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. Ann Hematol 2010;89:299-303
   PubMed Web of Science ®Google Scholar
• Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 1999;107:330-4
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 2006;133:622-7
   PubMed Web of Science ®Google Scholar
• Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998;66:29-37
   PubMed Web of Science ®Google Scholar
• Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995;59:1194-200
   PubMed Web of Science ®Google Scholar
• Popow I, Leitner J, Majdic O, et al. Assessment of batch to batch variation in polyclonal antithymocyte globulin preparations. Transplantation 2012;93:32-40
   PubMed Web of Science ®Google Scholar
• Popow I, Leitner J, Grabmeier-Pfistershammer K, et al. A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations. Am J Transplant 2013;13:3103-13
   PubMedGoogle Scholar
• Breitinger HH, Rojewski MT, Schrezenmeier H. Antibodies to glycosylphosphatidyl-inositol anchored proteins (GPI-AP) in antithymocyte and antilymphocyte globulin: possible role for the expansion of GPI-AP deficient cells in aplastic anemia. Ann Hematol 2009;88:889-95
   PubMedGoogle Scholar
• Jeong DC, Chung NG, Cho B, et al. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. Haematologica 2014;99:664-71
   PubMed Web of Science ®Google Scholar
• Sakamoto T, Obara N, Kurita N, et al. Effectiveness and safety of rabbit anti-thymocyte globulin in Japanese patients with aplastic anemia. Int J Hematol 2013;98:319-22
   PubMedGoogle Scholar
• Serefhanoglu S, Buyukasik Y, Purnak T, et al. A comparison of Jurkat cell-reactive anti-T lymphocyte globulin and fetal anti-thymocyte globulin preparations in the treatment of aplastic anemia. Med Princ Pract 2011;20:341-4
   PubMedGoogle Scholar
• Luo CJ, Gao YJ, Tang JY, et al. ATG-Fresenius S combined with cyclosporine a: an effective immunosuppressive therapy for children with aplastic anemia. J Pediatr Hematol Oncol 2014;36:374-8
   PubMedGoogle Scholar
• Afable MG, Shaik M, Sugimoto Y, et al. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica 2011;96:1269-75
   PubMed Web of Science ®Google Scholar
• Chen C, Xue HM, Xu HG, et al. Rabbit-antithymocyte globulin combined with cyclosporin A as a first-line therapy: improved, effective, and safe for children with acquired severe aplastic anemia. J Cancer Res Clin Oncol 2012;138:1105-11
   PubMedGoogle Scholar
• Atta EH, Dias DS, Marra VL, et al. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol 2010;89:851-9
   PubMed Web of Science ®Google Scholar
• Halkes C, Brand A, von dem Borne PA. Increasing the dose of rabbit-ATG does not lead to a higher response rate in the first-line treatment of severe aplastic anemia. Bone Marrow Transplant 2011;46:S373
   Google Scholar
• Kadia TM, Borthakur G, Garcia-Manero G, et al. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 2012;157:312-20
   PubMed Web of Science ®Google Scholar
• Höchsmann B, Neher C, Germing U, et al. Therapy of acquired aplastic anemia with rabbit antithymocyte globulin: a retrospective analysis by the working group on non-malignant disorders of the German Society of Hematology and Oncology (DGHO). Blood 2011;117:3434
   Google Scholar
• Karapinar DY, Karadas N, Ay Y, et al. Rabbit antithymocyte globulin treatment in childhood acquired severe aplastic anemia. Pediatr Hematol Oncol 2014;31:20-8
   PubMed Web of Science ®Google Scholar
• Vallejo C, Montessino P, Rosell M, et al. Comparison between lymphoglobuline and thymoglobuline-based immunosuppressive therapy as first-line treatment for patients with aplastic anemia. Blood 2009;114:3194
   Google Scholar
• Shin SH, Yoon JH, Yahng SA, et al. The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol 2013;92:817-24
   PubMedGoogle Scholar
• Scheinberg P, Townsley D, Dumitriu B, et al. Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia. Am J Hematol 2014;89:467-9
   PubMed Web of Science ®Google Scholar
• Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 1999;93:2191-5
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Sloand EM, Nunez O, et al. Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood 2003;102:3584-6
   PubMed Web of Science ®Google Scholar
• Li X, Shao Y, Ge M, et al. A promising immunosuppressive strategy of cyclosporine alternately combined with levamisole is highly effective for moderate aplastic anemia. Ann Hematol 2013;92:1239-47
   PubMedGoogle Scholar
• Schrezenmeier H, Marin P, Raghavachar A, et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol 1993;85:371-7
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005;36:947-50
   PubMed Web of Science ®Google Scholar
• Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011;118:2351-7
   PubMed Web of Science ®Google Scholar
• Marsh JC, Kulasekararaj AG. Management of the refractory aplastic anemia patient: what are the options? Blood 2013;122:3561-7
   PubMedGoogle Scholar
• Kosaka Y, Yagasaki H, Sano K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008;111:1054-9
   PubMed Web of Science ®Google Scholar
• Tichelli A. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol 1998;100:393-400
   PubMed Web of Science ®Google Scholar
• Marsh JC, Hows JM, Bryett KA, et al. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood 1987;70:1046-52
   PubMed Web of Science ®Google Scholar
• Gupta V, Gordon-Smith EC, Cook G, et al. A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous responders. Br J Haematol 2005;129:110-17
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood 1996;87:491-4
   PubMed Web of Science ®Google Scholar
• Tisdale JF, Dunn DE, Geller N, et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet 2000;356:1554-9
   PubMed Web of Science ®Google Scholar
• Tisdale JF, Maciejewski JP, Nunez O, et al. Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial. Blood 2002;100:4668-70
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Chen AR, Dorr D, et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood 2010;115:2136-41
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhang L, Jing L, et al. High-dose cyclophosphamide compared with antithymocyte globulin for treatment of acquired severe aplastic anemia. Exp Hematol 2013;41:328-34
   PubMed Web of Science ®Google Scholar
• Audino AN, Blatt J, Carcamo B, et al. High-dose cyclophosphamide treatment for refractory severe aplastic anemia in children. Pediatr Blood Cancer 2010;54:269-72
   PubMed Web of Science ®Google Scholar
• Jaime-Perez JC, Gonzalez-Llano O, Gomez-Almaguer D. High-dose cyclophosphamide in the treatment of severe aplastic anemia in children. Am J Hematol 2001;66:71
   PubMedGoogle Scholar
• Scheinberg P, Townsley D, Dumitriu B, et al. “Moderate” dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution. Blood 2014;124:2820-3
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Jenal G, Herrmann F, et al. Quantitative analysis of cobblestone area forming cells in bone marrow of patients with aplastic anemia by limiting dilution assay. Blood 1996;88:4474-80
   PubMed Web of Science ®Google Scholar
• Ziegler P, Schrezenmeier H, Akkad J, et al. Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation. Ann Hematol 2012;91:1115-20
   PubMed Web of Science ®Google Scholar
• Chuhjo T, Yamazaki H, Omine M, et al. Danazol therapy for aplastic anemia refractory to immunosuppressive therapy. Am J Hematol 2008;83:387-9
   PubMed Web of Science ®Google Scholar
• Jaime-Perez JC, Colunga-Pedraza PR, Gomez-Ramirez CD, et al. Danazol as first-line therapy for aplastic anemia. Ann Hematol 2011;90:523-7
   PubMed Web of Science ®Google Scholar
• Hochsmann B, Moicean A, Risitano A, et al. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant 2013;48:168-73
   PubMedGoogle Scholar